查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602658

阿尔法甘露甘露醣储积症市场：按治疗类型、适应症和最终用户划分 - 全球预测 2025-2030

Alpha Mannosidosis Market by Treatment Type (Bone Marrow Transplant, Enzyme Replacement Therapy), Indication (Type I, Type II, Type III), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年α-甘露醣储积症市值为68.1亿美元，预计到2024年将达到74.9亿美元，复合年增长率为10.82%，到2030年将达到139.8亿美元。

α-甘露甘露醣储积症是一种罕见的遗传性疾病，由 MAN2B1 基因突变引起，会导致溶小体储存问题。这种疾病会导致从智能障碍到骨骼异常等一系列症状。该市场包括治疗这些症状的疗法、酵素替代疗法和支持性护理。市场成长的需求是由对新疗法的需求和早期诊断的进步所推动的。研究应用主要是为了提高病患的生活品质和延长寿命，最终用途主要是在专业医疗机构和研究机构。市场成长受到人们认识的提高、对罕见疾病的资助以及基因组和分子医学的进步的影响。随着孤儿药认定和津贴等监管激励措施的不断增加，机会已经成熟。此外，生物技术公司和医疗保健提供者之间的伙伴关係对于促进治疗方法的开发和可近性至关重要。然而，市场扩张受到高昂的治疗成本、有限的患者群体以及严格的监管途径（延长新疗法的上市时间）的限制。一个关键的挑战是缺乏全面的全球登记系统阻碍了对患者群体的了解。创新的最佳方向是开发具有成本效益和患者友好的治疗方法，重点是基因治疗和精准医学。此外，在临床试验中使用巨量资料和人工智慧有可能缩短开发时间。公司还有潜力创新病人参与平台，以提高依从性和结果。该市场以患者为中心且高度专业化，需要研究机构、製药公司和患者权益团体之间的密切合作。公司可以在此类利基市场中策略性地定位自己，因为利用这些动态并投资于强有力的相关人员合作和以患者为中心的解决方案可以推动市场成长。

主要市场统计
基准年[2023] 68.1亿美元
预测年份 [2024] 74.9亿美元
预测年份 [2030] 139.8亿美元
复合年增长率（%） 10.82%

市场动态：快速发展的阿尔法-甘露醣储积症市场的关键市场洞察

供需的动态交互作用正在改变α-甘露醣储积症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 提高大众对α-甘露醣储积症的认识
    • 加大对现代化医疗基础设施的投资
  • 市场限制因素
    • α-甘露醣储积症症治疗相关的高成本
  • 市场机会
    • 酵素替代疗法治疗罕见遗传疾病的兴起
    • α-甘露甘露醣储积症症治疗药物的核准增加
  • 市场挑战
    • 与缺乏熟练医疗保健专业人员相关的问题

波特的五力：驾驭阿尔法-甘露醣储积症市场的战略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对α-甘露醣储积症市场的外部影响

外部宏观环境因素在塑造α-甘露醣储积症市场表现动态中发挥至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解阿尔法甘露醣储积症市场的竞争状况

对阿尔法甘露醣储积症市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵α甘露醣储积症市场供应商绩效评估

FPNV定位矩阵是评估α甘露醣储积症市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，绘製阿尔法-甘露醣储积症市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对阿尔法甘露醣储积症市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 大众对α-甘露醣储积症的认识不断提高。
      • 加大现代化医疗基础建设投入
    • 抑制因素
      • α-甘露醣储积症症治疗相关的高成本
    • 机会
      • 新的酵素替代疗法出现用于治疗罕见遗传疾病
      • α-甘露甘露醣储积症药品产品核可数量增加
    • 任务
      • 与熟练医疗保健专业人员短缺有关的问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 α-甘露甘露醣储积症的市场治疗类型

  • 骨髓移植
  • 酵素替代疗法

第七章依适应症分類的α-甘露醣储积症市场

  • Ⅰ型
  • II型
  • Ⅲ型

第 8 章 阿尔法甘露醣储积症市场：依最终用户分类

  • 医院
  • 专科诊所

第九章北美和南美阿尔法甘露甘露醣储积症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区阿尔法甘露醣储积症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的阿尔法甘露醣储积症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Chiesi Farmaceutici SpA
  • Cigna Corporation
  • CVS Caremark
  • Kamada Ltd.
  • Orient Europharma（M）Sdn Bhd
  • Talaris Therapeutics Inc.
Product Code: MRR-C002B1C99848

The Alpha Mannosidosis Market was valued at USD 6.81 billion in 2023, expected to reach USD 7.49 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 13.98 billion by 2030.

Alpha Mannosidosis is a rare genetic disorder caused by mutations in the MAN2B1 gene, leading to lysosomal storage issues. This condition results in a spectrum of symptoms from intellectual disabilities to skeletal abnormalities. The market scope involves therapeutic drugs, enzyme replacement therapies, and supportive care addressing these symptoms. Necessity for market growth is driven by the demand for novel treatments and advances in early diagnosis. Applications primarily focus on improving patient quality of life and extending lifespan, with end-use primarily seen in specialized healthcare facilities and research institutions. Market growth is influenced by increased awareness, funding for rare diseases, and advancements in genomics and molecular medicine. Opportunities are ripe given the increase in regulatory incentives like orphan drug designations and grants. Moreover, partnerships between biotech firms and healthcare providers are essential to expedite therapy development and accessibility. However, market expansion faces limitations like high treatment costs, limited patient populations, and stringent regulatory pathways that can elongate the time-to-market for new treatments. A significant challenge is the current lack of comprehensive global registries that hinders understanding of patient demographics. Innovation is best directed towards developing cost-effective and patient-friendly therapies with the focus on gene therapies and precision medicine. Moreover, leveraging big data and AI in clinical trials could potentially reduce development times. Businesses could also innovate in patient engagement platforms, enhancing adherence and outcomes. The nature of this market is patient-centric and highly specialized, calling for robust collaborations between research institutions, pharmaceutical companies, and patient advocacy groups. Navigating these dynamics and investing in robust stakeholder collaborations and patient-centric solutions can propel market growth, making it imperative for firms to strategically position themselves in these niche areas.

KEY MARKET STATISTICS
Base Year [2023] USD 6.81 billion
Estimated Year [2024] USD 7.49 billion
Forecast Year [2030] USD 13.98 billion
CAGR (%) 10.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alpha Mannosidosis Market

The Alpha Mannosidosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing awareness of alpha mannosidosis among population
    • Increasing investment to develop modern healthcare infrastructure
  • Market Restraints
    • High cost associated with alpha mannosidosis treatments
  • Market Opportunities
    • Emerging enzyme replacement therapy to treat rare genetic disorders
    • Rising product approvals for alpha mannosidosis medications
  • Market Challenges
    • Issues associated with dearth of skilled healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Alpha Mannosidosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alpha Mannosidosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alpha Mannosidosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alpha Mannosidosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alpha Mannosidosis Market

A detailed market share analysis in the Alpha Mannosidosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alpha Mannosidosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alpha Mannosidosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alpha Mannosidosis Market

A strategic analysis of the Alpha Mannosidosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alpha Mannosidosis Market, highlighting leading vendors and their innovative profiles. These include Chiesi Farmaceutici S.p.A., Cigna Corporation, CVS Caremark, Kamada Ltd., Orient Europharma (M) Sdn Bhd, and Talaris Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Alpha Mannosidosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Bone Marrow Transplant and Enzyme Replacement Therapy.
  • Based on Indication, market is studied across Type I, Type II, and Type III.
  • Based on End-User, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness of alpha mannosidosis among population
      • 5.1.1.2. Increasing investment to develop modern healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with alpha mannosidosis treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging enzyme replacement therapy to treat rare genetic disorders
      • 5.1.3.2. Rising product approvals for alpha mannosidosis medications
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with dearth of skilled healthcare professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alpha Mannosidosis Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Bone Marrow Transplant
  • 6.3. Enzyme Replacement Therapy

7. Alpha Mannosidosis Market, by Indication

  • 7.1. Introduction
  • 7.2. Type I
  • 7.3. Type II
  • 7.4. Type III

8. Alpha Mannosidosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics

9. Americas Alpha Mannosidosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alpha Mannosidosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alpha Mannosidosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Chiesi Farmaceutici S.p.A.
  • 2. Cigna Corporation
  • 3. CVS Caremark
  • 4. Kamada Ltd.
  • 5. Orient Europharma (M) Sdn Bhd
  • 6. Talaris Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. ALPHA MANNOSIDOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. ALPHA MANNOSIDOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALPHA MANNOSIDOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALPHA MANNOSIDOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, 2023